ClinicalTrials.gg
RecruitingNCT07015112AMIDA-ICHUpdated Jun 11, 2025

Applying a Multidisciplinary Intervention for Drug Adequacy in an Intermediate Care Hospital (AMIDA-ICH)

An interventional study of Patient-centered multidisciplinary treatment review in Poly Pharmacy and Frail Elderly, sponsored by Parc Sanitari Pere Virgili. Recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by Parc Sanitari Pere Virgili · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 4 months after the study started (first participant enrolled Jan 2024, registered Jun 2025).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.

Planned enrollment
9th of 96
300 · median 90
Started
2024
with 13 others
No phase
93 of 132
34 open now
Primary completion
2025-12
later than 17 of 53 live
Registered
93rd of 132
by date

Among the 132 studies in Frailty with a site in Spain, this one is the 9th largest by planned enrollment of the 96 interventional ones that give a count, is one of 14 that started in 2024, is one of 93 with no phase, reaches primary completion later than 17 of the 53 other live ones, and was the 93rd registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Frailty with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a multi-professional (conducted by geriatricians, clinical pharmacists, nurses) medication revision, centered on patients' goals and characteristics, can improve treatment adequacy in older adults admitted to an intermediate care hospital.

The main question it aims to answer is: does this approach reduce the average number of medications taken per patient?

Researchers will compare this multi-professional patient-centered revision to the usual standard of care (treatment revision conducted by a clinical pharmacist) to see if the patient-centered revision works in improving treatment adequacy.

Participants admitted to an intermediate care hospital will undergo a comprehensive assessment by a geriatrician, and a medication revision (conducted by a multidisciplinary team or a clinical-pharmacist alone). They will also be asked to fulfill some questionnaires on their health status and attitudes. Any possible adverse events to the medications will be recorded at discharge. Participants will be contacted again three months after discharge to check for any readmission or death.

03

Conditions studied

  • Poly Pharmacy
  • Frail Elderly

Keywords

  • polypharmacy
  • frailty
  • adverse drug event
  • deprescribing
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • older adults (65+ years)
  • ≥ 3 or more chronic conditions requiring medical therapy
  • able to speak Spanish
  • capacity to provide or have a surrogate able to consent on their behalf

Exclusion criteria

Exclusion Criteria:

  • unable to provide
  • anticipated length of hospital stay \< 72h
  • estimated \< 3 months
  • homeless
  • already enrolled in a drug trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • No intervention
    Control (usual care)

    Control arm will receive usual standard of care

  • Experimental
    Intervention (patient-centered medication review)

    Intervention arm will receive a multidisciplinary patient-centered medication review

    Other: Patient-centered multidisciplinary treatment review

Interventions

  • OtherPatient-centered multidisciplinary treatment review

    Patient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy)

06

What researchers measure

Primary outcomes

  1. Number of drugs

    Median number of drugs per patient

    Time frame: Baseline and after discharge, an average of 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 23 months is close to that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2025
First posted
Jun 11, 2025
StartActual
Jan 4, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07015112
Lead sponsor
Parc Sanitari Pere Virgili
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jan 4, 2024
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jun 11, 2025

Study contacts

Ana M de Andrés Lázaro, Pharmacist. PhD
Contact
amandres@perevirgili.cat
+34932594128

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion